9/12/2025

Shares of genetic testing company Natera (NASDAQ:NTRA). fell 2.7% in the afternoon session after the company reached an $8.25 million settlement in a legal case. The case, titled 'Amanda Davis v. Natera Inc.,' was reported by the Daily Journal. While the financial impact of the settlement may not be substantial for a company of Natera's scale, news of legal disputes can create uncertainty among investors. The announcement may have raised concerns regarding the underlying issues of the lawsuit or

Source: Yahoo

9/11/2025

As of September 2025, the U.S. stock market is experiencing a mixed performance, with the S&P 500 and Nasdaq reaching new closing highs while the Dow Jones Industrial Average sees a decline ahead of key inflation data releases. In this environment of fluctuating indices and economic indicators, identifying stocks that may be trading below their estimated value can provide investors with potential opportunities for growth. Understanding what constitutes an undervalued stock in such conditions...

Source: Yahoo

9/10/2025

Shares of genetic testing company Natera (NASDAQ:NTRA). fell 4.1% in the afternoon session after a key competitor, Exact Sciences, announced the launch of a new multi-cancer early detection blood test.

Source: Yahoo

9/10/2025

Discover Natera’s latest advances in MRD testing, women’s health diagnostics, and global

Source: SeekingAlpha

9/10/2025

Since September 2020, the S&P 500 has delivered a total return of 94.8%. But one standout stock has doubled the market - over the past five years, Natera has surged 186% to $176.64 per share. Its momentum hasn’t stopped as it’s also gained 33.2% in the last six months thanks to its solid quarterly results, beating the S&P by 17.2%.

Source: Yahoo

9/8/2025

Natera (NTRA) just revealed that its personalized, tumor-informed Signatera test is now part of the NRG Oncology ARCHER phase III trial for muscle-invasive bladder cancer. This development is catching the eye of both clinicians and investors. The ARCHER study spans more than 100 sites across the US and Canada, with Natera’s MRD technology integrated directly into its exploration of new standards of care. For anyone watching the cancer diagnostics space, this move is more than just another...

Source: Yahoo

9/2/2025

Duquesne Family Office's Q2 2025 portfolio updates: key bets in tech & healthcare, new positions, and Druckenmiller's trend-driven investment strategy. See more.

Source: SeekingAlpha

9/2/2025

Discover why Natera (NTRA) stands out in biotech with revenue growth, no long-term debt, and specialized testing. Click here to read my most recent analysis.

Source: SeekingAlpha

9/2/2025

Liquid Biopsy Market Liquid Biopsy Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Market by Product & Service (Kits, Instruments), Circulating Biomarker (ctDNA, cfDNA, CTC), Technology (NGS, PCR), Application (Lung, Breast, Prostate Cancer), Sample Type (Blood, Urine, CSF), End User (Hospitals) - Global Forecast to 2030" has been added to ResearchAndMarkets.com's offering. The liquid biopsy market is anticipated to surge, estimated to reach USD 7.05 billion by 2030, growing

Source: Yahoo

9/2/2025

Natera, Inc. (NASDAQ:NTRA) is one of the best hot large cap stocks to buy according to hedge funds. On August 29, Natera, Inc. (NASDAQ:NTRA) provided an update on its intellectual property litigation with NeoGenomics, Inc., announcing that the US District Court for the Middle District of North Carolina issued a ruling “invalidating certain claims in […]

Source: Yahoo

8/29/2025

Find insight on NeoGenomics, Summerset, Ramsay Health Care, Cooper Cos., Summerset and more in the latest Market Talks covering health care.

Source: Yahoo

8/29/2025

Shares of genetic testing company Natera (NASDAQ:NTRA). fell 0.9% in the morning session after the company announced an unfavorable court ruling in its ongoing patent litigation with competitor NeoGenomics.

Source: Yahoo

8/29/2025

Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) jumped 22.5% in the morning session after a court ruled in the company's favor in a patent infringement lawsuit against Natera.

Source: Yahoo

8/29/2025

On Friday, the District Court for the Middle District of North Carolina issued a ruling invalidating specific claims in two patents that Natera Inc. (NASDAQ:NTRA) asserted against NeoGenomics, Inc.'s (NASDAQ:NEO) v1.1 RaDaR test. Natera said on Friday that it is evaluating its options, including an appeal and further enforcement with other patents. Natera said these patents are distinct from U.S. Patent No. 11,519,035 (the ‘035 patent), and the decision has no impact on the validity or enforceab

Source: Yahoo

8/29/2025

AUSTIN, Texas, August 29, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today provided an update regarding its intellectual property litigation with NeoGenomics, Inc.

Source: Yahoo

8/29/2025

As of August 2025, the U.S. stock market is experiencing a remarkable upswing, with key indices like the S&P 500 and Dow Jones Industrial Average reaching record highs amid anticipation of a significant inflation report. In this thriving environment, identifying high-growth tech stocks involves looking for companies that demonstrate robust earnings potential and adaptability to current economic conditions, particularly those leveraging advancements in AI and digital infrastructure.

Source: Yahoo

8/29/2025

FORT MYERS, Fla., August 29, 2025--Court Rules for NeoGenomics in Patent Infringement Lawsuit Against Natera

Source: Yahoo

8/29/2025

The trial will assess if shorter radiation matches current outcomes in muscle-invasive bladder cancer, using Signatera for MRD monitoring.

Source: Yahoo

8/28/2025

Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 3% in the afternoon session after the company announced its Signatera molecular residual disease test was selected for a Phase III clinical trial for muscle-invasive bladder cancer.

Source: Yahoo

8/28/2025

AUSTIN, Texas, August 28, 2025--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a randomized, phase III study in muscle-invasive bladder cancer (MIBC). The study is evaluating whether a shorter course of radiation can achieve outcomes comparable to the current standard of care. It prospectively incorporates Signatera, Natera’s personalized, tumor-informed molecular residual disease

Source: Yahoo